BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor. 2024

Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.

Oncogenic KRAS mutations drive an approximately 25 % of all human cancers. Son of Sevenless 1 (SOS1), a critical guanine nucleotide exchange factor, catalyzes the activation of KRAS. Targeting SOS1 degradation has engaged as a promising therapeutic strategy for KRAS-mutant cancers. Herein, we designed and synthesized a series of novel CRBN-recruiting SOS1 PROTACs using the pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor as the warhead. One representative compound 11o effectively induced the degradation of SOS1 in three different KRAS-mutant cancer cell lines with DC50 values ranging from 1.85 to 7.53 nM. Mechanism studies demonstrated that 11o-induced SOS1 degradation was dependent on CRBN and proteasome. Moreover, 11o inhibited the phosphorylation of ERK and displayed potent anti-proliferative activities against SW620, A549 and DLD-1 cells. Further optimization of 11o may provide us promising SOS1 degraders with favorable drug-like properties for developing new chemotherapies targeting KRAS-driven cancers.

UI MeSH Term Description Entries

Related Publications

Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
November 2000, Journal of medicinal chemistry,
Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
Pyrido[2,3-d]pyrimidin-7(8H)-ones: Synthesis and Biomedical Applications.
November 2019, Molecules (Basel, Switzerland),
Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors.
June 2016, European journal of medicinal chemistry,
Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-inflammatory FMS inhibitors.
April 2008, Bioorganic & medicinal chemistry letters,
Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors.
February 2024, Journal of medicinal chemistry,
Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
6-(2,6-Dimethyl-phen-yl)pyrido[2,3-d]pyrimidin-7-amine.
February 2009, Acta crystallographica. Section E, Structure reports online,
Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
June 2008, Bioorganic & medicinal chemistry,
Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
Synthesis and antitumor activity of novel pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-one derivatives.
June 2011, European journal of medicinal chemistry,
Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
Synthesis of 4-substituted pyrido[2,3-d]pyrimidin-4(1H)-one as analgesic and anti-inflammatory agents.
July 2009, Bioorganic & medicinal chemistry letters,
Kun Wang, and Zehui Zhou, and Xinyi Ma, and Jiahang Xu, and Wangyang Xu, and Guizhen Zhou, and Chuan Zhou, and Huajie Li, and Mingyue Zheng, and Sulin Zhang, and Tianfeng Xu
Pyrido[2,3-d]pyrimidin-4(3H)-one derivatives and 1,2,3,4-tetrahydro- pyrido[2,3-d]pyrimidine derivatives: synthesis and in vitro study of their activity against platelet aggregation.
November 1995, Die Pharmazie,
Copied contents to your clipboard!